Placebo News and Research

RSS

Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms

Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19.

22 Nov 2023

Study shows how probiotic Bifidobacteria longum can help relieve constipation

Scientists have identified the genes in the probiotic Bifidobacteria longum responsible for improving gut motility.

21 Nov 2023

Drug for children with achondroplasia may help reduce chances of SIDS

A drug that boosts bone growth in children with the most common form of dwarfism, may also reduce their chances of sudden infant death syndrome, sleep apnea and needing surgery, according to a new study.

21 Nov 2023

Autism research needs more high-quality randomized studies, meta-analysis finds

A new meta-analysis led by Micheal Sandbank, PhD, an assistant professor in the Department of Health Sciences at the UNC School of Medicine, found that the field of autism needs more high-quality randomized studies of early interventions to help clinicians understand how to better support children diagnosed with the condition.

21 Nov 2023

Novel antidepressant zuranolone effective in alleviating depression and anxiety symptoms

The efficacy and safety of zuranolone in treating major depressive disorder (MDD).

20 Nov 2023

Oral antibiotic taken once-daily for six months reduces risk of developing drug-resistant TB

Two landmark clinical trials reported today at the Union meeting showed that an oral antibiotic taken for six months once-daily substantially reduced the risk of developing drug-resistant TB.

16 Nov 2023

New study reveals turmeric and Tinospora Cordifolia reduce liver injury risk in TB patients

The effectiveness of herbs and alternative medicines in preventing liver injury induced by anti-tuberculosis (anti-TB) drugs.

16 Nov 2023

Cannabis shows promise in easing endometriosis pain, new research suggests

The Journal of Clinical Medicine review explores cannabis as a self-management strategy for endometriosis pain, revealing its potential to reduce gut inflammation and improve gut permeability, thereby alleviating bloating and suppressing pain through interactions with the endocannabinoid system and gut microbiota.

14 Nov 2023

Anti-inflammatory medication does not reduce frailty risk in adults with atherosclerosis

Frailty is a common condition in older populations that increases the risk of adverse health outcomes and mortality.

14 Nov 2023

Aspirin avoidance improves clinical outcomes in patients with advanced heart failure

Left ventricular assist devices (LVADs) are pumps that are used to circulate blood in patients with weakened hearts due to advanced heart failure. Mechanical stress on these implants can make patients susceptible to blood clots, and patients are required to take anti-clotting medications including vitamin-k antagonists (VKA) and aspirin.

14 Nov 2023

High-dose CBD fails to relieve pain in knee osteoarthritis patients

Cannabidiol (CBD) is marketed by some suppliers as a painkiller, e.g. for osteoarthritis of the knee. Animal experiments have shown that the substance, which is extracted from the hemp plant, has an anti-inflammatory and pain-relieving effect in arthritis.

14 Nov 2023

Neural circuits respond to rapid dopamine surges

Researchers assess the pharmacodynamics of dopamine signaling, brain connectivity/activity, and self-documented 'high' following methylphenidate exposure.v

14 Nov 2023

Optimal hydration post-exercise: Study compares sodium and carbohydrate levels in sports drinks for effective rehydration

In this study, researchers compared the effectiveness of sports drinks with varying carbohydrate and sodium levels for rehydrating athletes post-exercise, finding that drinks with higher sodium and lower carbohydrate content were more effective for rapid and complete rehydration. The study highlighted the importance of beverage composition in athlete recovery and hydration strategies.

13 Nov 2023

Recaticimab injection every 1-3 months may safely lower bad cholesterol

A new PCSK9 inhibitor (recaticimab) injected every one to three months may work safely and provide more flexible dosing to lower cholesterol, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

New drug zilebesiran effectively lowers blood pressure for six months, study finds

A single injection of the experimental medication zilebesiran was safe and effective in reducing systolic blood pressure in people with mild-to-moderate high blood pressure for up to six months, as detailed in the Phase 2 of the KARDIA study, reported as late-breaking science today at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

Single injection of new medication effectively eliminates Lp(a) for nearly one year

In the first human trial of a new therapeutic, a single injection of lepodisiran reduced levels of lipoprotein(a), or Lp(a), to undetectable levels for nearly one year, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes.

13 Nov 2023

UK regulator approves a diabetes drug for weight management in obese and overweight patients

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (8 November 2023) authorised via a national application route, a new indication for the diabetes medicine, Mounjaro (tirzepatide), for weight loss and weight management in adults aged 18 and over.

13 Nov 2023

Study suggests concomitant antidepressant and statin use could prevent treatment discontinuation

A recent study in the journal BMC Medicine evaluates the real-world impact of combining antidepressants with statins in UK adults, revealing lower discontinuation rates but similar efficacy compared to antidepressant-only treatment.

12 Nov 2023

Obinutuzumab shows promise in preserving kidney function, preventing flares in lupus nephritis patients

In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab-;an antibody that targets a protein expressed on certain immune cells-;was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney condition associated with the autoimmune disease lupus.

10 Nov 2023

Placebo News and Research

Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms

Study shows how probiotic Bifidobacteria longum can help relieve constipation

Drug for children with achondroplasia may help reduce chances of SIDS

Autism research needs more high-quality randomized studies, meta-analysis finds

Novel antidepressant zuranolone effective in alleviating depression and anxiety symptoms

Oral antibiotic taken once-daily for six months reduces risk of developing drug-resistant TB

New study reveals turmeric and Tinospora Cordifolia reduce liver injury risk in TB patients

Cannabis shows promise in easing endometriosis pain, new research suggests

Anti-inflammatory medication does not reduce frailty risk in adults with atherosclerosis

Aspirin avoidance improves clinical outcomes in patients with advanced heart failure

High-dose CBD fails to relieve pain in knee osteoarthritis patients

Neural circuits respond to rapid dopamine surges

Optimal hydration post-exercise: Study compares sodium and carbohydrate levels in sports drinks for effective rehydration

Recaticimab injection every 1-3 months may safely lower bad cholesterol

New drug zilebesiran effectively lowers blood pressure for six months, study finds

Single injection of new medication effectively eliminates Lp(a) for nearly one year

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

UK regulator approves a diabetes drug for weight management in obese and overweight patients

Study suggests concomitant antidepressant and statin use could prevent treatment discontinuation

Obinutuzumab shows promise in preserving kidney function, preventing flares in lupus nephritis patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News